Clinical Trial

ALPINE: Maintenance Letrozole/Abemaciclib

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53) wild-type endometrial cancer. The names of the study drugs involved in this study are: * Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor) * Letrozole (a type of aromatase inhibitor)
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-04-12; most recent amendment 2026-02-09.
Status change: Not Yet Recruiting → Recruiting 2024-07-31
Trial Details
NCT Number NCT06366347
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Eli Lilly and Company
Conditions Endometrial Cancer, Recurrent Endometrial Cancer, TP53
Enrollment 32 participants
Start Date 2024-09-25
Primary Completion 2027-09-01 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-11